Zacks Investment Research on MSN2d
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
It has been about a month since the last earnings report for Biogen Inc. (BIIB). Shares have added about 1.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...
Zacks Investment Research on MSN2d
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...
The Nasdaq is Cratering But REGN, BIIB and CSGP Are Up Big Today
Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...
Biogen Inc. stock underperforms Wednesday when compared to competitors
Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Steward Partners Investment Advisory LLC
Steward Partners Investment Advisory LLC lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 31.8% during the 4th quarter, according to its most recent disclosure with the ...
TD Cowen Remains a Buy on Biogen (BIIB)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Nasdaq4d
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated ...
Yahoo Finance13d
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Even with the cheaper entry price, we're cautious about Biogen. Here are three reasons why BIIB doesn't excite us and a stock we'd rather own. Founded in 1978 in Switzerland as one of the first ...
4BIIB, LLY : Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed...
NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...
Biogen (BIIB) Receives a Hold from Bernstein
In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...
Decoding Biogen's Options Activity: What's the Big Picture?
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...
Nasdaq17d
April 11th Options Now Available For Biogen (BIIB)
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...